David Matthews

Title: David Matthews: Innovator in Monoclonal Antibody Development

Introduction

David Matthews is a prominent inventor based in Sheffield, GB. He has made significant contributions to the field of biotechnology, particularly in the development of humanised monoclonal antibodies. With a total of 5 patents to his name, Matthews has focused on innovations that have the potential to impact the treatment of serious diseases such as Alzheimer's and cancer.

Latest Patents

Among his latest patents, the "Humanised anti-n-truncated amyloid β monoclonal antibody" stands out. This invention relates to humanised antibodies that bind to amyloid peptides, featuring mutations in the heavy chain and/or light chain variable domains that enhance binding activity. These antibodies may prove useful in treating Alzheimer's disease (AD). Another notable patent is the "Humanised anti-IL17BR antibody," which pertains to humanised versions of the murine anti-IL17BR antibody D9.2. This invention includes mutations that improve expression without negatively affecting specificity or affinity. The humanised antibodies may include specific heavy and light chain variable domains, making them valuable in cancer treatment.

Career Highlights

David Matthews has worked with notable organizations such as LifeArc and the University Medical Center Göttingen. His work in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Some of his coworkers include Alex Brown and Tim Johnson, who have collaborated with him on various projects, enhancing the scope and impact of his inventions.

Conclusion

David Matthews is a key figure in the field of monoclonal antibody research, with a focus on developing innovative solutions for complex medical challenges. His contributions are paving the way for advancements in treatments for Alzheimer's disease and cancer.